Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236847 | 0.83 | CA12 (0.48) | CA12CA1CA9SYKRORC | |
| SCHEMBL12931080 | 0.83 | CYP17A1 (0.37) | HTTCA12CA1CA9EGFR | |
| SCHEMBL10228068 | 0.83 | TSHR (0.40) | HTTEGFRAURKBSYKRORC | |
| SCHEMBL793197 | 0.83 | ATR (0.42) | HTTCA12CA1CA9EGFR | |
| SCHEMBL8571236 | 0.82 | CA12 (0.43) | CA12CA1CA9CYP17A1ATR | |
| SCHEMBL12931081 | 0.82 | CYP17A1 (0.36) | HTTCA12CA1CA9EGFR | |
| SCHEMBL23140326 | 0.82 | EGLN2 (0.44) | HTTCA12CA1CA9EGFR | |
| SCHEMBL3202901 | 0.82 | HTT (0.62) | HTTEGFRAURKBRORCTSHR | |
| SCHEMBL12228592 | 0.82 | AR (0.49) | HTTCA12CA1CA9EGFR | |
| SCHEMBL29666354 | 0.82 | AR (0.49) | HTTCA12CA1CA9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059169-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-113444063-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113321632-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-2890375-B1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-07-28 | — | — | EP | disclosed |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-05-04 | — | — | US | disclosed |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-28 | — | — | US | disclosed |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-08-13 | — | — | US | disclosed |
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-06-09 | — | — | US | disclosed |
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-06 | — | — | US | disclosed |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-24 | — | — | US | disclosed |
| CN-104902885-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | JANSSEN R & D IRELAND | 2015-09-09 | — | — | CN | disclosed |
| CN-104812743-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC IE | 2015-07-29 | — | — | CN | disclosed |
| EP-2890688-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890375-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014184365-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184350-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014033176-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033170-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | HTT 2493/4885CA12 3211/4885CA1 4327/4885 |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | HTT 2493/4885CA12 3211/4885CA1 4327/4885 |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | HTT 2001/4885CA12 3171/4885CA1 3259/4885 |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | HTT 2493/4885CA12 3211/4885CA1 4327/4885 |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | HTT 2493/4885CA12 3211/4885CA1 4327/4885 |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | HTT 2493/4885CA12 3211/4885CA1 4327/4885 |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | HTT 2493/4885CA12 3211/4885CA1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.